{"doi":"10.1210/clinem/dgac588","title":"Treatment of Cushing Disease With Pituitary-Targeting Seliciclib","abstract":"CONTEXT: Preclinical studies show seliciclib (R-roscovitine) suppresses neoplastic corticotroph proliferation and pituitary adrenocorticotrophic hormone (ACTH) production. OBJECTIVE: To evaluate seliciclib as an effective pituitary-targeting treatment for patients with Cushing disease (CD). METHODS: Two prospective, open-label, phase 2 trials, conducted at a tertiary referral pituitary center, included adult patients with de novo, persistent, or recurrent CD who received oral seliciclib 400 mg twice daily for 4 consecutive days each week for 4 weeks. The primary endpoint in the proof-of-concept single-center study was normalization of 24-hour urinary free cortisol (UFC; ≤ 50 µg/24 hours) at study end; in the pilot multicenter study, primary endpoint was UFC normalization or ≥ 50% reduction in UFC from baseline to study end. RESULTS: Sixteen patients were consented and 9 were treated. Mean UFC decreased by 42%, from 226.4 ± 140.3 µg/24 hours at baseline to 131.3 ± 114.3 µg/24 hours by study end. Longitudinal model showed significant UFC reductions from baseline to each treatment week. Three patients achieved ≥ 50% UFC reduction (range, 55%-75%), and 2 patients exhibited 48% reduction; none achieved UFC normalization. Plasma ACTH decreased by 19% (P = 0.01) in patients who achieved ≥ 48% UFC reduction. Three patients developed grade ≤ 2 elevated liver enzymes, anemia, and/or elevated creatinine, which resolved with dose interruption/reduction. Two patients developed grade 4 liver-related serious adverse events that resolved within 4 weeks of seliciclib discontinuation. CONCLUSION: Seliciclib may directly target pituitary corticotrophs in CD and reverse hypercortisolism. Potential liver toxicity of seliciclib resolves with treatment withdrawal. The lowest effective dose requires further determination.","journal":"The Journal of Clinical Endocrinology & Metabolism","year":2022,"id":248646,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":30,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9571,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":324067,"name":"Anat Ben-Shlomo","orcid":"0000-0002-2912-5355","position":1,"is_corresponding":false},{"id":509789,"name":"John D. Carmichael","orcid":"0000-0002-3194-9249","position":2,"is_corresponding":false},{"id":278839,"name":"Christina Wang","orcid":"0000-0002-8231-792X","position":3,"is_corresponding":false},{"id":278836,"name":"Ronald S. Swerdloff","orcid":"0000-0001-6084-6604","position":4,"is_corresponding":false},{"id":241815,"name":"Anthony P. Heaney","orcid":"0000-0003-3865-0810","position":5,"is_corresponding":false},{"id":761094,"name":"Garni Barkhoudarian","orcid":"0000-0002-6615-7428","position":6,"is_corresponding":false},{"id":448828,"name":"Daniel F. Kelly","orcid":"0000-0002-8358-056X","position":7,"is_corresponding":false},{"id":291021,"name":"Mazen Noureddin","orcid":"0000-0003-2127-2040","position":8,"is_corresponding":false},{"id":888118,"name":"Lin Lü","orcid":"0000-0003-3379-8277","position":9,"is_corresponding":false},{"id":888778,"name":"Manish Desai","orcid":null,"position":10,"is_corresponding":false},{"id":888779,"name":"Yana Stolyarov","orcid":null,"position":11,"is_corresponding":false},{"id":311872,"name":"Kevin C.J. Yuen","orcid":"0000-0002-8169-2728","position":12,"is_corresponding":false},{"id":254816,"name":"Adam N. Mamelak","orcid":"0000-0002-4245-6431","position":13,"is_corresponding":false},{"id":888119,"name":"James Mirocha","orcid":"0000-0002-2338-193X","position":14,"is_corresponding":false},{"id":465524,"name":"Mourad Tighiouart","orcid":"0000-0001-8021-5690","position":15,"is_corresponding":false},{"id":311874,"name":"Шломо Мелмед","orcid":"0000-0002-2355-3447","position":16,"is_corresponding":false},{"id":888777,"name":"Ning‐Ai Liu","orcid":null,"position":0,"is_corresponding":true}],"reference_count":24,"raw_metadata":null,"created_at":"2026-07-19T00:24:14.794521Z","pmid":"36214832","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}